4-55396241-C-A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_018475.5(TMEM165):c.52C>A(p.Leu18Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000243 in 1,496,596 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_018475.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TMEM165 | ENST00000381334.10 | c.52C>A | p.Leu18Met | missense_variant | 1/6 | 1 | NM_018475.5 | ENSP00000370736.5 | ||
TMEM165 | ENST00000506198.5 | c.52C>A | p.Leu18Met | missense_variant | 1/3 | 2 | ENSP00000425449.1 | |||
TMEM165 | ENST00000508404.5 | n.52C>A | non_coding_transcript_exon_variant | 1/7 | 2 | ENSP00000422639.1 | ||||
TMEM165 | ENST00000514070.1 | n.-10C>A | upstream_gene_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.000250 AC: 38AN: 152074Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000214 AC: 22AN: 102576Hom.: 0 AF XY: 0.000239 AC XY: 14AN XY: 58688
GnomAD4 exome AF: 0.000242 AC: 326AN: 1344522Hom.: 0 Cov.: 34 AF XY: 0.000272 AC XY: 181AN XY: 664308
GnomAD4 genome AF: 0.000250 AC: 38AN: 152074Hom.: 0 Cov.: 32 AF XY: 0.000283 AC XY: 21AN XY: 74288
ClinVar
Submissions by phenotype
TMEM165-congenital disorder of glycosylation Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 21, 2022 | This sequence change replaces leucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 18 of the TMEM165 protein (p.Leu18Met). This variant is present in population databases (rs756276628, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with TMEM165-related conditions. ClinVar contains an entry for this variant (Variation ID: 976570). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 05, 2023 | The c.52C>A (p.L18M) alteration is located in exon 1 (coding exon 1) of the TMEM165 gene. This alteration results from a C to A substitution at nucleotide position 52, causing the leucine (L) at amino acid position 18 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 09, 2024 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at